ALS-Biomarkers is an observational study that aims to collect a range of biomarkers, including bloods, saliva, and urine from people with motor neuron disease (MND), also known as amyotrophic lateral sclerosis (ALS). This is a trial led by University College London, with sites across the UK, and aims to build a large nationwide collection of samples.
These samples will be used to identify possible biomarkers that can help with the diagnosing MND and predicting disease progression. This includes, for example, distinguishing MND from other disorders, assessing and identifying variability in progression rates, and as a marker of progression for therapeutic responses and clinical trials.
ALS-Biomarkers will also assess the feasibility of using remote collection of blood, urine, and saliva samples to help further understand the biology behind MND.
